EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity

Tzu-Yu Huang, Meng-Ru Wang, Feng-Pai Chou, Sheng-Cih Huang, Po-Yun Hsiao, Tung-Kung Wu iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70251 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2026. Written by Tzu-Yu Huang and 5 co-authors. Institution: Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan. Major MEDLINE topics: Aromatase Inhibitors, Estrone, Triple Negative Breast Neoplasms, Antineoplastic Agents. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Science and Technology, Taiwan, National Science and Technology Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aromatase inhibitors (AIs) are vital in the treatment of estrogen‐dependent breast cancer, especially in postmenopausal women. In this study, a series of steroidal glycosides (SGs) derived from trans ‐androsterone ( t AND), estrone (E1), and estradiol (E2) were synthesized using a one‐pot multi‐enzyme glycosylation approach and structurally characterized via HPLC, MS, and NMR. Among the synthesized compounds, E1‐α‐2DG ( 2b ) and E2‐α‐2DG ( 3b ) demonstrated the most potent aromatase inhibition, with IC 50 values of 0.101 ± 0.001 μM and 0.159 ± 0.009 μM, respectively. Molecular docking revealed that these glycosides form key hydrogen bonds with catalytic residues and the heme group of CYP19A1. In vitro cytotoxicity showed that E1‐α‐2DG selectively inhibited the growth of MCF‐7 and MDA‐MB‐231 breast cancer cells in a dose‐dependent manner, with the highest potency observed against triple‐negative MDA‐MB‐231 cells (IC 50 = 20.46 ± 2.92 μM), while exhibiting no toxicity toward non‐cancerous HEK293 cells. These findings suggest that glycosylation enhances the pharmacological potential of steroidal scaffolds and highlights E1‐α‐2DG as a promising lead compound for the development of safer, dual‐function breast cancer therapies.

Subjects

MeSH terms (MEDLINE)

Aromatase InhibitorsEstroneTriple Negative Breast NeoplasmsAntineoplastic AgentsGlucosidesHumansAromataseFemaleMolecular Docking SimulationMDA-MB-231 CellsMCF-7 CellsCell Line, TumorCell Proliferation

Author keywords

aromatase inhibitorsendocrine therapyestradiolestronesteroidal glycosidetrans‐androsterone

Substances

AromataseAromatase InhibitorsEstroneAntineoplastic AgentsGlucosides

Authors and institutions

  • Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan.
  • Center for Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
  • Center for Intelligent Drug Systems and Smart Bio-Devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan.

ORCID profiles: Tung-Kung Wu

Funding

  • Ministry of Science and Technology, Taiwan
  • National Science and Technology Council

Cite

APA

Huang, T. Y., Wang, M. R., Chou, F. P., Huang, S. C., Hsiao, P. Y., & Wu, T. K. (2026). Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70251

Vancouver

Huang TY, Wang MR, Chou FP, Huang SC, Hsiao PY, Wu TK. Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70251

BibTeX
@article{Huang2026,
  author = {Huang, Tzu-Yu and Wang, Meng-Ru and Chou, Feng-Pai and Huang, Sheng-Cih and Hsiao, Po-Yun and Wu, Tung-Kung},
  title = {Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70251}
}
Start for free →